Brillia Health Cold-flu Recovery

Lapine Histamine Immune Globulin (12c, 30c, 50c), Lapine Interferon Gamma Immune Globulin (12c, 30c, 50c), Lapine Cd4 Immune Globulin (12c, 30c, 50c)


Hadaf Llc
Human Otc Drug
NDC 72123-006
Brillia Health Cold-flu Recovery also known as Lapine Histamine Immune Globulin (12c, 30c, 50c), Lapine Interferon Gamma Immune Globulin (12c, 30c, 50c), Lapine Cd4 Immune Globulin (12c, 30c, 50c) is a human otc drug labeled by 'Hadaf Llc'. National Drug Code (NDC) number for Brillia Health Cold-flu Recovery is 72123-006. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Brillia Health Cold-flu Recovery drug includes Lapine Cd4 Immune Globulin - 12 [hp_C]/1 Lapine Histamine Immune Globulin - 12 [hp_C]/1 Lapine Interferon Gamma Immune Globulin - 12 [hp_C]/1 . The currest status of Brillia Health Cold-flu Recovery drug is Active.

Drug Information:

Drug NDC: 72123-006
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Brillia Health Cold-flu Recovery
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lapine Histamine Immune Globulin (12c, 30c, 50c), Lapine Interferon Gamma Immune Globulin (12c, 30c, 50c), Lapine Cd4 Immune Globulin (12c, 30c, 50c)
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Hadaf Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LAPINE CD4 IMMUNE GLOBULIN - 12 [hp_C]/1
LAPINE HISTAMINE IMMUNE GLOBULIN - 12 [hp_C]/1
LAPINE INTERFERON GAMMA IMMUNE GLOBULIN - 12 [hp_C]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 31 Jul, 2020
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 06 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Hadaf LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:UIF41K6WR9
7U4T47R0DD
Q2KS2OI6SA
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
72123-006-012 BLISTER PACK in 1 BOX (72123-006-01) / 20 TABLET in 1 BLISTER PACK31 Jul, 2020N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose homeopathic, enhance magnitude of immune response reduce histamine and inflammation response enhance functional activity of immune system

Product Elements:

Brillia health cold-flu recovery lapine histamine immune globulin (12c, 30c, 50c), lapine interferon gamma immune globulin (12c, 30c, 50c), lapine cd4 immune globulin (12c, 30c, 50c) lactose monohydrate microcrystalline cellulose magnesium stearate lapine interferon gamma immune globulin lapine interferon gamma immune globulin lapine histamine immune globulin lapine histamine immune globulin lapine cd4 immune globulin lapine cd4 immune globulin round tablets other

Indications and Usage:

Uses • shorten the duration of flu and cold symptoms • reduce severity of flu and cold symptoms, including nasal congestion, cough and sore/itchy throat

Warnings:

Warnings ask a doctor or pharmacist before use if you are lactose-intolerant. stop use and ask a doctor if symptoms persist or worsen. if pregnant or breast-feeding , ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away. a llergic (hypersensitivity) reactions may occur i n very rare cases. do not use if known sensitivity to brillia health cold-flu recovery or any of its ingredients exists.

Do Not Use:

Warnings ask a doctor or pharmacist before use if you are lactose-intolerant. stop use and ask a doctor if symptoms persist or worsen. if pregnant or breast-feeding , ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away. a llergic (hypersensitivity) reactions may occur i n very rare cases. do not use if known sensitivity to brillia health cold-flu recovery or any of its ingredients exists.

Dosage and Administration:

Directions • for adults and children 1 year and older. • hold tablet in mouth until completely dissolved, without food. if necessary, tablet can be taken dissolved in 1 tablespoon of drinking water. • day 1: 8 tablets total for the first day 1 tablet every 30 minutes for the first 2 hours (a total of 5 tablets over 2 hours), 1 tablet taken 3 more times at equal intervals (a total of 3 tablets over the remainder of the day). • days 2 to 5: 1 tablet 3 times a day (at equal intervals).

Stop Use:

Stop use and ask a doctor if symptoms persist or worsen.

Adverse Reactions:

Allergic reaction allergic (hypersensitivity) reactions may occur i n very rare cases.

Package Label Principal Display Panel:

40 tablets ndc: 72123-006-01 label 1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.